# SWOG S1826

Source: https://onco.cc/trials/swog-s1826/  
OnCo record `swog-s1826` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunotherapy plus chemotherapy beat the previous best regimen with far less nerve damage, in the first Hodgkin trial to enrol children and adults together; approved March 2026.

## Summary

1-year PFS 94% vs 86%; 2-year PFS 92% vs 83% (HR 0.45, NEJM 2024). Peripheral neuropathy 28.1% vs 54.2%; fewer treatment discontinuations. Radiotherapy given to <1%. FDA approval 20 March 2026 for ages 12+. Now the frontline standard for advanced-stage disease in North America; HD21's BrECADD is the European alternative.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT03907488
- Phase: 3
- Setting: Untreated stage III-IV classical Hodgkin lymphoma, age ≥12: nivolumab + AVD vs brentuximab vedotin + AVD
- Sponsor: SWOG / NCI (with COG)
- Enrolled: 994
- Result: 2-year PFS 92% vs 83%, HR 0.45.
- Outcomes: Progression-free survival at 2 years: Nivolumab-AVD 92% vs BV-AVD 83%, HR 0.45; Any-grade peripheral neuropathy: Nivolumab-AVD 28.1% vs BV-AVD 54.2%
- Replication: Consistent with phase 2 N-AVD data (CheckMate 205 cohort D) and with pembrolizumab-AVD single-arm studies; no second randomised trial yet.

## Sources

- ClinicalTrials.gov NCT03907488: https://clinicaltrials.gov/study/NCT03907488
- FDA approval (Mar 2026): https://www.targetedonc.com/view/fda-approves-nivolumab-plus-avd-for-classical-hodgkin-lymphoma

## Connected records

- collections: [Targeted Oncology](https://onco.cc/collections/src-targeted-oncology/)
- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/), [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- people: [Alex F. Herrera](https://onco.cc/people/alex-herrera/), [Kara M. Kelly](https://onco.cc/people/kara-kelly/)
- pairings: [PD-1 blockade + AVD chemotherapy](https://onco.cc/pairings/pd1-plus-avd-hodgkin/)
- terms: [British and American lymphoma practice: where they differ, and why](https://onco.cc/terms/lymphoma-tx-uk-versus-us/), [Escalated chemotherapy or ABVD in advanced Hodgkin lymphoma: more cures, more late harm, and what the interim scan changed](https://onco.cc/terms/lymphoma-decision-beacopp-or-abvd/)
- key papers: [ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/), [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/swog-s1826.json